Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumococcal vaccine GSK513026 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | ACTIVE_COMPARATOR | - |
| Group B | EXPERIMENTAL | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Group E | EXPERIMENTAL | - |
| Group F | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pneumococcal vaccine GSK513026 | BIOLOGICAL | Two-dose intramuscular injection. Five different formulations, each administered to one Group |
| Pneumovax 23™ | BIOLOGICAL | Single dose intramuscular injection. |
Inclusion criteria * Subjects who the investigator believes will comply with the requirements of the protocol * A male or female ≥ 65 years at the time of the first vaccination. * Written informed consent obtained from the subject. * Free of obvious health problems as established by medical history...
Pneumococcal vaccine GSK513026 is an investigational vaccine developed by GSK plc for prophylaxis of invasive pneumococcal diseases and pneumonia. It is a vaccine candidate that has been studied in a Phase 2 clinical trial in an elderly population. It is not an approved product.
Pneumococcal vaccine GSK513026 is being developed for prophylaxis of invasive pneumococcal diseases and pneumonia. The clinical program has focused on elderly adults, with the completed Phase 2 trial enrolling participants aged 65 years and older. It is intended to prevent pneumococcal disease rather than treat it.
Pneumococcal vaccine GSK513026 is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this investigational pneumococcal vaccine candidate.
Pneumococcal vaccine GSK513026 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed for this candidate. It is an investigational vaccine and has not been approved for any indication.
Pneumococcal vaccine GSK513026 has been evaluated in one completed Phase 2 trial, NCT00307528, titled Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population. The trial enrolled 146 participants in Belgium, was randomized and active controlled, and included adults aged 65 years and older.
The Phase 2 trial NCT00307528 was a randomized, active controlled study of Pneumococcal vaccine GSK513026 in adults aged 65 years and older. It enrolled 146 participants in Belgium, included healthy volunteers, and has been completed. The study assessed safety and efficacy for prophylaxis of invasive pneumococcal diseases and pneumonia.